Kunjin replicon based vaccines for HIV

基于 Kunjin 复制子的 HIV 疫苗

• 批准号: nhmrc : 290240
• 负责人: A/Pr David Harrich
• 金额: $ 22.93万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2006-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/kunjin-replicon-based-vaccines-hiv/101474
• 关键词: Kunjin; replicon; based; vaccines; HIV

In recent years it has become clear that certain white blood cells called CD8+ T lymphocytes or killer T cells are required to protect people against HIV. Unfortunately, current vaccines that produce or anti-HIV CD8 T cells only produce effective T cells for a short period. In this project we intend to test a novel vaccine vector called a Kunjin replicon, which promises to persistently produce or maintain effective T cells because the vaccine itself persists and continually immunises for extended periods. We intend to test the ability of this vaccine to persist and persistently produce effective CD8 T cells not only systemically in the blood system but also at mucosal surfaces, where HIV usually gains entry during sexual intercourse.

近年来，人们已经清楚地认识到，某些称为CD8+ T淋巴细胞或杀伤T细胞的白色血细胞是保护人们免受艾滋病毒感染所必需的。不幸的是，目前生产或抗HIV CD8 T细胞的疫苗只能在短时间内产生有效的T细胞。在这个项目中，我们打算测试一种名为Kunjin复制子的新型疫苗载体，它有望持续产生或维持有效的T细胞，因为疫苗本身持续存在并持续免疫很长一段时间。我们打算测试这种疫苗不仅在血液系统中而且在粘膜表面持续产生有效的CD8 T细胞的能力，HIV通常在性交期间进入粘膜表面。